• Tammy T Nguyen, Michelle Troendle, Kirk Cumpston, S Rutherfoord Rose, and Brandon K Wills.
• Division of Clinical Toxicology, Department of Emergency Medicine, VCU Medical Center, Richmond, VA 23298; Virginia Poison Center, Richmond, VA 23298; Department of Emergency Medicine, VCU Medical Center, Richmond, VA 23298. Electronic address: TammyNguyenT@gmail.com.
• Am J Emerg Med. 2015 Nov 1;33(11):1677-9.

BackgroundFlumazenil is an effective benzodiazepine (BZD) antagonist. Empiric use of flumazenil in the emergency department (ED) is not widely recommended due to concerns of seizures, which are commonly associated with coingestants and BZD withdrawal.ObjectiveThe objective of the study is to assess adverse events and clinical outcomes of flumazenil administration in known and suspected BZD overdose in an ED at a tertiary academic medical center.MethodsThis is a retrospective observational study of adult patients administered flumazenil for known or suspected BZD overdose in the ED over 7 years. Outcomes included mental status improvement, the incidence of seizures, and intubation of the trachea after flumazenil administration.ResultsTwenty-three patients were included in the analysis, of which 15 (65%) of patients experienced some type of clinically significant mental status improvement. No seizures were identified despite 7 (35%) reported proconvulsant coingestants. One patient required intubation of the trachea but was subsequently extubated in the ED.ConclusionsA majority of patients had improved mental status after the administration of flumazenil. No patient experienced seizures. Additional studies that clarify the role of flumazenil for ED patients with suspected BZD toxicity are warranted.Copyright © 2015 Elsevier Inc. All rights reserved.

31 keywords...

hide…